Evidence map›Paper›PMID 28002473›Full record

ArticlePLoS pathogens2016

Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine.

Neil Berry, Maria Manoussaka, Claire Ham, Deborah Ferguson, Hannah Tudor, Giada Mattiuzzo, Bep Klaver, Mark Page, Richard Stebbings, Atze T Das and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Variable BaselineFrontiers in immunology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Neil BerryDivision of Virology, National Institute for Biological Standards and Control, South Mimms, United Kingdom.
Maria ManoussakaInstitute for Infection & Immunity, St George's, University of London, London, United Kingdom.
Claire HamDivision of Virology, National Institute for Biological Standards and Control, South Mimms, United Kingdom.
Deborah FergusonDivision of Virology, National Institute for Biological Standards and Control, South Mimms, United Kingdom.
Hannah TudorDivision of Virology, National Institute for Biological Standards and Control, South Mimms, United Kingdom.
Giada MattiuzzoDivision of Virology, National Institute for Biological Standards and Control, South Mimms, United Kingdom.
Bep KlaverLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Mark PageDivision of Virology, National Institute for Biological Standards and Control, South Mimms, United Kingdom.
Richard StebbingsDivision of Biotherapeutics, National Institute for Biological Standards and Control, South Mimms, United Kingdom.
Atze T DasLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Ben BerkhoutLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Neil AlmondDivision of Virology, National Institute for Biological Standards and Control, South Mimms, United Kingdom.
Martin P CranageInstitute for Infection & Immunity, St George's, University of London, London, United Kingdom.
National Institute for Biological Standards and Control · GBSt George's, University of London · GBUniversity of Amsterdam · NLAcademic Medical Center · NL

Funding

Medical Research Council G0600007Medical Research Council G0601201Medical Research Council G9025730
6 · The paper itself

Abstract

In order to evaluate the role of persisting virus replication during occult phase immunisation in the live attenuated SIV vaccine model, a novel SIVmac239Δnef variant (SIVrtTA) genetically engineered to replicate in the presence of doxycycline was evaluated for its ability to protect against wild-type SIVmac239. Indian rhesus macaques were vaccinated either with SIVrtTA or with SIVmac239Δnef. Doxycycline was withdrawn from 4 of 8 SIVrtTA vaccinates before challenge with wild-type virus. Unvaccinated challenge controls exhibited ~107 peak plasma viral RNA copies/ml persisting beyond the acute phase. Six vaccinates, four SIVmac239Δnef and two SIVrtTA vaccinates exhibited complete protection, defined by lack of wild-type viraemia post-challenge and virus-specific PCR analysis of tissues recovered post-mortem, whereas six SIVrtTA vaccinates were protected from high levels of viraemia. Critically, the complete protection in two SIVrtTA vaccinates was associated with enhanced SIVrtTA replication in the immediate post-acute vaccination period but was independent of doxycycline status at the time of challenge. Mutations were identified in the LTR promoter region and rtTA gene that do not affect doxycycline-control but were associated with enhanced post-acute phase replication in protected vaccinates. High frequencies of total circulating CD8+T effector memory cells and a higher total frequency of SIV-specific CD8+ mono and polyfunctional T cells on the day of wild-type challenge were associated with complete protection but these parameters were not predictive of outcome when assessed 130 days after challenge. Moreover, challenge virus-specific Nef CD8+ polyfunctional T cell responses and antigen were detected in tissues post mortem in completely-protected macaques indicating post-challenge control of infection. Within the parameters of the study design, on-going occult-phase replication may not be absolutely required for protective immunity.

Indexed as

AnimalsImmunohistochemistryImmunophenotypingMacaca mulattaPolymerase Chain ReactionSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaccines, AttenuatedVirus ReplicationSAIDS VaccinesVaccines, Attenuated

Identifiers

PMID28002473
PMCPMC5176322
OpenAlexW2564255635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.